Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Tue Apr 01 17:27:37 GMT 2025
by
admin
on
Tue Apr 01 17:27:37 GMT 2025
|
| Protein Sub Type | |
| Sequence Type | COMPLETE |
| Record UNII |
UE9PX4FTL0
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
UE9PX4FTL0
Created by
admin on Tue Apr 01 17:27:37 GMT 2025 , Edited by admin on Tue Apr 01 17:27:37 GMT 2025
|
PRIMARY | |||
|
P28222
Created by
admin on Tue Apr 01 17:27:37 GMT 2025 , Edited by admin on Tue Apr 01 17:27:37 GMT 2025
|
PRIMARY | |||
|
P28222
Created by
admin on Tue Apr 01 17:27:37 GMT 2025 , Edited by admin on Tue Apr 01 17:27:37 GMT 2025
|
PRIMARY |
| From | To |
|---|---|
| 1_122 | 1_199 |
| Glycosylation Type | HUMAN |
| Glycosylation Link Type | Site |
|---|---|
| N | 1_24 |
| N | 1_32 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARTIAL AGONIST->TARGET |
Emax=55%
Ki
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Natural agonist
IC50
|
||
|
AGONIST -> TARGET |
|
||
|
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET | |||
|
INHIBITOR -> TARGET |
INHIBITOR
Ki
|
||
|
LIGAND->TARGET |
Kd
|
||
|
|
AGONIST -> TARGET | |||
|
INHIBITOR -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
INHIBITOR -> TARGET |
INHIBITOR
Ki
|
||
|
AGONIST -> TARGET |
BINDING
IC50
|
||
|
RADIOLIGAND->TARGET |
Kd
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
|
INHIBITOR -> TARGET |
|
||
|
RADIOLIGAND->TARGET |
Kd
|
||
|
AGONIST -> TARGET |
IC50
|
||
|
INHIBITOR -> TARGET | |||
|
|
AGONIST -> TARGET | |||
|
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
BINDING
IC50
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR->OFF-TARGET |
BINDING
IC50
|
||
|
RADIOLIGAND->TARGET |
(11C)P943 is a new radioligand recently developed to image and quantify serotonin 5-Hydroxytryptamine (5-HT1B) receptors with positron emission tomography (PET). The purpose of this study was to evaluate (11C)P943 for this application in humans, and to determine the most suitable quantification method. (11C)P943 is suitable to quantify 5-HT1B receptors in humans in vivo. (11C)P943 binding potentials are significantly correlated with in vitro measurements of the density of 5-HT1B receptors, and in vivo estimates of the (11C)P943 dissociation constant Kd are close to in vitro measurements. Using arterial input functions, MA1 is the method of choice, especially for parametric images computation. Among noninvasive methods, MRTM2* is the preferred method.
Ki
|
||
|
|
AGONIST -> TARGET |
|
||
|
ANTAGONIST->TARGET | |||
|
INHIBITOR -> TARGET |
IC50
|
![Structure of (3R)-1-[6-(2,3-dihydroxypentan-3-yl)pyridin-3-yl]-3-[[2-(4-methylpiperazin-1-yl)phenyl]methyl]pyrrolidin-2-one](/img/52241ba9-175b-4b81-99b1-18b33c032b1f.svg "Structure of (3R)-1-[6-(2,3-dihydroxypentan-3-yl)pyridin-3-yl]-3-[[2-(4-methylpiperazin-1-yl)phenyl]methyl]pyrrolidin-2-one")
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT | CHEMICAL |
|